Cordlife launches MetaScreen Metabolic Screening Service

New service MetaScreen allows detection of as many as 110 metabolic disorders from urine samples.

November 22, 2013 2:12 IST | India Infoline News Service
Cordlife Group Limited, a multi-product healthcare company catering to the mother and child segment, announced today that its Indian subsidiary Cordlife Sciences India Pvt. Ltd, has launched an advanced non-invasive metabolic screening service known as MetaScreen. This service will be made available to through major nursing homes and Cordlife clients.

MetaScreen is a comprehensive set of metabolic screening test specially designed for both newborn babies and adults. The service can detect as many as 110 inborn errors of metabolism from urine samples. Metabolic disorders are usually not apparent at the time of birth. If left undiagnosed and untreated, the baby can develop irreversible damages such as neurological impairment and physical deformities. Hence, early detection is critical in preventing adverse effects and providing essential care. Most countries in the European Union and some parts of Asia and United States have already made newborn screening compulsory.

Just as newborn screening is widely recognised by medical professionals as an essential healthcare service , the fast-rising growing middle class in India are becoming increasingly aware of the importance of their children’s healthcare needs as shown by the 2007–2011 Compounded Annual Growth Rate of annual incremental storage units for private cord blood banks of 35%.

MetaScreen is a natural extension of Indian parents’ desire for better healthcare options for their children. Providing parents with early critical information on the health.

FREE Benefits Worth 5,000



Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity